ECM2 Inhibitors

Tyrosine kinase inhibitors like Genistein and Dasatinib, which impact the cellular pathways involving adhesion and migration that are crucial for the function and positioning of ECM2 within the extracellular matrix. The inclusion of matrix metalloprotease inhibitors such as Marimastat and GM6001 is based on their ability to prevent the degradation of ECM components, thereby potentially influencing the stability and presence of ECM2. Furthermore, inhibitors like LY294002, SB203580, and PD98059 target the intracellular signaling cascades such as PI3K, p38 MAPK, and MEK, respectively, which are known to regulate cellular responses that could affect ECM2's role. In addition, compounds like SP600125, NSC23766, and Y-27632 are included for their ability to modulate the cytoskeletal dynamics and cell motility, thereby influencing the structural integrity and function of ECM2 in the extracellular matrix. The Src kinase inhibitors PP2 and Dasatinib, along with the EGFR inhibitor AG1478, play a role in the regulation of cell-extracellular matrix interactions that ECM2 is a part of. By inhibiting these kinases, the chemicals can alter the signaling pathways that dictate the cellular interactions with the ECM, thereby modulating the function of ECM2.